[Effectiveness of treatment of recurrences of non-Hodgkin's lymphoma after combined chemoradiotherapy depending on prognostic indicators]
- PMID: 11826503
[Effectiveness of treatment of recurrences of non-Hodgkin's lymphoma after combined chemoradiotherapy depending on prognostic indicators]
Abstract
The results were evaluated of the management of non-Hodgkin's lymphomas in 46 out of 150 patients relapsing after first complete remission, following early-stage chemoradiotherapy. Polychemotherapy of recurrent tumors was given to 85% (39/46), repeat combined treatment--13% (6/46) and radiotherapy--2% (1/46). Remission was reported in 91% (42/46): complete--69% (32) and partial--22% (10). Remission frequency and duration directly depended on degree of risk (IPI), stage of recurrence development and advancement, tumor size and general symptoms of intoxication. There was no relationship between frequency and duration, on the one hand, and sex and age, tumor pattern or number of involvement areas, on the other. Instead, the efficacy was influenced by the general condition of the patient, damage to the lymph nodes rather than adjacent areas as well as number of such areas. LDH blood level impacted the end results.
Similar articles
-
[Primary extranodal non-Hodgkin's lymphoma of the head and neck].Recenti Prog Med. 1997 Apr;88(4):169-72. Recenti Prog Med. 1997. PMID: 9206813 Italian.
-
[Clinical characteristics and prognosis of diffuse large B-cell lymphoma].Zhonghua Zhong Liu Za Zhi. 2005 Mar;27(3):174-6. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 15946571 Chinese.
-
Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma.Strahlenther Onkol. 2003 Oct;179(10):694-701. doi: 10.1007/s00066-003-1062-8. Strahlenther Onkol. 2003. PMID: 14566478
-
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.J Clin Oncol. 2003 Jun 1;21(11):2115-22. doi: 10.1200/JCO.2003.07.111. J Clin Oncol. 2003. PMID: 12775737 Review.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.